• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
OncoTherapy Science, Inc. - Product Pipeline Review - Q4 2010 Product Image

OncoTherapy Science, Inc. - Product Pipeline Review - Q4 2010

  • Published: December 2010
  • 35 pages
  • Global Markets Direct

OncoTherapy Science, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “OncoTherapy Science, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- OncoTherapy Science, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of OncoTherapy Science, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the READ MORE >



List of Tables
List of Figures
OncoTherapy Science, Inc. Snapshot
OncoTherapy Science, Inc. Overview
Key Information
Key Facts
OncoTherapy Science, Inc. – Research and Development Overview
Key Therapeutic Areas
OncoTherapy Science, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
OncoTherapy Science, Inc. – Pipeline Products Glance
OncoTherapy Science, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
OncoTherapy Science, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
OncoTherapy Science, Inc. – Drug Profiles
OTS102 + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
A0041
Product Description
Mechanism of Action
R&D Progress
B5860N
Product Description
Mechanism of Action
R&D Progress
C2093
Product Description
Mechanism of Action
R&D Progress
C6776
Product Description
Mechanism of Action
R&D Progress
D0587
Product Description
Mechanism of Action
R&D Progress
OncoTherapy Science, Inc. – Pipeline Analysis
OncoTherapy Science, Inc. – Pipeline Products by Therapeutic Class
OncoTherapy Science, Inc. Pipeline Products By Target
OncoTherapy Science, Inc. – Pipeline Products by Route of Administration
OncoTherapy Science, Inc. – Pipeline Products by Molecule Type
OncoTherapy Science, Inc. - Dormant Projects
OncoTherapy Science, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Deals Landscape
OncoTherapy Science, Inc., Deals Volume Summary, 2004 to YTD 2010
OncoTherapy Science, Inc., Deals Summary By Region, 2004 to YTD 2010
OncoTherapy Science, Inc., Deals Summary, 2004 to YTD 2010
OncoTherapy Science, Inc. Detailed Deal Summary
OncoTherapy Science Enters Into Research Agreement With Carna Biosciences And CrystalGenomics
Yakult Honsha Enters Into Co-Development Agreement With OncoTherapy Science
Licensing Agreements
Shionogi Enters Into A License Agreement With OncoTherapy Science
OncoTherapy Science Enters Into Licensing Agreement With Institute for Antibodies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS